Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H23ClN2O2 |
Molecular Weight | 382.883 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)N1CCC(CC1)=C2C3=CC=C(Cl)C=C3CCC4=C2N=CC=C4
InChI
InChIKey=JCCNYMKQOSZNPW-UHFFFAOYSA-N
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
Molecular Formula | C22H23ClN2O2 |
Molecular Weight | 382.883 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=11023307
Curator's Comment: The second generation antihistamines were less soluble in lipid and thus less readily penetrated the blood-brain barrier
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7581058 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CLARITIN Approved UseUses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •itchy, watery eyes •sneezing •itching of the nose or throat Launch Date1993 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
27.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/ |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 ng/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
96 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/ |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
56.9 ng × h/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/ |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
27 h |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84.5% |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 |
Other AEs: Somnolence, Headache... Other AEs: Somnolence (10%) Sources: Headache (9%) Fatigue (5%) Dry mouth (4%) |
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Other AEs: Fatigue, Fever... Other AEs: Fatigue (2%) Sources: Fever (7%) Headache (5%) Influenza-like symptoms (2%) Constipation (2%) Diarrhea (3%) Dyspepsia (2%) Loose stools (2%) Stomatitis (2%) Tooth disorder (2%) Vomiting (5%) Earache (2%) Drowsiness (7%) Infection viral (2%) Allergic rhinitis (2%) Coughing (3%) Epistaxis (3%) Pharyngitis (3%) Rash (2%) |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 35.3 |
Other AEs: Headache... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Somnolence | 10% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 |
Dry mouth | 4% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 |
Fatigue | 5% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 |
Headache | 9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 |
Allergic rhinitis | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Constipation | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Dyspepsia | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Earache | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Fatigue | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Infection viral | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Influenza-like symptoms | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Loose stools | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Rash | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Stomatitis | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Tooth disorder | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Coughing | 3% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Diarrhea | 3% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Epistaxis | 3% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Pharyngitis | 3% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Headache | 5% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Vomiting | 5% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Drowsiness | 7% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Fever | 7% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: |
Headache | 4.2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 35.3 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0 |
no | |||
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/10597902/ Page: 11.0 |
no | |||
no | ||||
yes [IC50 0.61 uM] | ||||
yes [IC50 0.76 uM] | ||||
yes [IC50 11 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/ Page: 6.0 |
yes [IC50 3.36 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10597902/ Page: 1,8 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 1.0 |
major | yes (co-administration study) Comment: Coadministration with either ketoconazole, erythromycin (both CYP3A4 inhibitors) increased AUC of drug by 307%, 40%, respectively; coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103% Page: 1.0 |
||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
Page: 1.0 |
minor | yes (co-administration study) Comment: coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103% Page: 1.0 |
||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. | 1999 Dec 15 |
|
Central nervous system effects of H1-receptor antagonists in the elderly. | 1999 Feb |
|
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. | 1999 Jan |
|
Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups. | 1999 Jun |
|
Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years' duration. | 1999 Sep |
|
Antiallergic effects of H1-receptor antagonists. | 2000 |
|
Mechanism responsible for epileptogenic activity by first-generation H1-antagonists in rats. | 2000 Dec 22 |
|
Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. | 2000 Jan |
|
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction. | 2001 |
|
Desloratadine in the treatment of chronic idiopathic urticaria. | 2001 |
|
Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. | 2001 |
|
Safety of antihistamines in children. | 2001 |
|
Evaluation of a four-channel multiplexed electrospray triple quadrupole mass spectrometer for the simultaneous validation of LC/MS/MS methods in four different preclinical matrixes. | 2001 Apr 15 |
|
Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma. | 2001 Apr 20 |
|
Newer antihistamines. | 2001 Apr 30 |
|
[A new antihistamine. Inhibiting inflammation in rhinorrhea and nasal congestion]. | 2001 Apr 5 |
|
Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. | 2001 Aug |
|
Applications of new liquid chromatography-tandem mass spectrometry technologies for drug development support. | 2001 Aug 10 |
|
Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. | 2001 Dec |
|
Antihistamines and serum adhesion molecule levels. | 2001 Jun |
|
High-dose loratadine exposure in a six-year-old child. | 2001 Jun |
|
Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. | 2001 Mar |
|
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. | 2001 Mar |
|
Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine. | 2001 May |
|
Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus. | 2001 May 11 |
|
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. | 2001 Nov |
|
Effect of specific immunotherapy versus loratadine on serum adhesion molecules. | 2001 Oct |
|
Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. | 2001 Oct |
|
Controlled clinical study of the efficacy of loratadine in Nigerian patients with allergic rhinitis. | 2001 Sep |
|
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. | 2002 |
|
Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. | 2002 Apr |
|
A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. | 2002 Jan |
|
The effect of loratadine in exercise-induced asthma. | 2002 Jan |
|
Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. | 2002 Jan 1 |
|
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. | 2002 Jun |
|
Med-psych drug-drug interactions update. | 2002 Mar-Apr |
|
Ventricular tachycardia following ingestion of a commonly used antihistamine. | 2002 May 6 |
Sample Use Guides
Adults and children 6 years and over: 1 tablet daily; not more than 1 tablet in 24 hours
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7510965
dose-dependent inhibition of histamine release was observed at loratadine dose above 7 UM. In the rat basophilic leukemia cells (RBL-2H3) experimental system, inhibition by loratadine increased when the concentration of extracellular Ca2+ was reduced from 1.8 to 0.45 mM. Loratadine also inhibited the Mn2+ influx into these cells, thus reflecting the Ca2+ influx.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:54 GMT 2025
by
admin
on
Mon Mar 31 18:00:54 GMT 2025
|
Record UNII |
7AJO3BO7QN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R06AX13
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
||
|
WHO-VATC |
QR06AX13
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
||
|
LIVERTOX |
NBK548831
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID2023224
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
7216
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
758628
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
100000092179
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
5864
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
79794-75-5
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
1370270
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
3957
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
m6905
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
1605
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
D017336
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
Loratadine
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
7AJO3BO7QN
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
SUB08581MIG
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
3578
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
W-119
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
28889
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | RxNorm | ||
|
CHEMBL998
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
7AJO3BO7QN
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
DB00455
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
LORATADINE
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
C29162
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
PARENT->INNOVATOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||